Review



methylcellulose-based medium methocult h4034 optimum  (STEMCELL Technologies Inc)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    STEMCELL Technologies Inc methylcellulose-based medium methocult h4034 optimum
    Methylcellulose Based Medium Methocult H4034 Optimum, supplied by STEMCELL Technologies Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/methylcellulose-based medium methocult h4034 optimum/product/STEMCELL Technologies Inc
    Average 90 stars, based on 1 article reviews
    methylcellulose-based medium methocult h4034 optimum - by Bioz Stars, 2026-04
    90/100 stars

    Images



    Similar Products

    r0739s methylcellulose based medium  (New England Biolabs)
    98
    New England Biolabs r0739s methylcellulose based medium
    R0739s Methylcellulose Based Medium, supplied by New England Biolabs, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/r0739s methylcellulose based medium/product/New England Biolabs
    Average 98 stars, based on 1 article reviews
    r0739s methylcellulose based medium - by Bioz Stars, 2026-04
    98/100 stars
    		  Buy from Supplier
    methylcellulose-based medium methocult h4034 optimum  (STEMCELL Technologies Inc)
    90
    STEMCELL Technologies Inc methylcellulose-based medium methocult h4034 optimum
    Methylcellulose Based Medium Methocult H4034 Optimum, supplied by STEMCELL Technologies Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/methylcellulose-based medium methocult h4034 optimum/product/STEMCELL Technologies Inc
    Average 90 stars, based on 1 article reviews
    methylcellulose-based medium methocult h4034 optimum - by Bioz Stars, 2026-04
    90/100 stars
    		  Buy from Supplier
    semi-solid methylcellulose medium methocult h4230  (STEMCELL Technologies Inc)
    90
    STEMCELL Technologies Inc semi-solid methylcellulose medium methocult h4230
    Semi Solid Methylcellulose Medium Methocult H4230, supplied by STEMCELL Technologies Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/semi-solid methylcellulose medium methocult h4230/product/STEMCELL Technologies Inc
    Average 90 stars, based on 1 article reviews
    semi-solid methylcellulose medium methocult h4230 - by Bioz Stars, 2026-04
    90/100 stars
    		  Buy from Supplier
    methylcellulose medium methocult h4034  (STEMCELL Technologies Inc)
    90
    STEMCELL Technologies Inc methylcellulose medium methocult h4034
    Methylcellulose Medium Methocult H4034, supplied by STEMCELL Technologies Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/methylcellulose medium methocult h4034/product/STEMCELL Technologies Inc
    Average 90 stars, based on 1 article reviews
    methylcellulose medium methocult h4034 - by Bioz Stars, 2026-04
    90/100 stars
    		  Buy from Supplier
    methylcellulose medium  (STEMCELL Technologies Inc)
    90
    STEMCELL Technologies Inc methylcellulose medium
    Combination of Q/M-induced proapoptotic activity is p53-dependent, and the combination treatment impairs clonogenicity in FLT3 mutant/ TP53 WT leukemia blasts. A, MOLM-13-p53-Vec or MOLM-13-p53-KD cells were treated with increasing concentrations of single-agent milademetan or quizartinib or Q/M combination for 48 hours. Apoptosis was measured by FCM with annexin V staining. CIs were calculated using CalcuSyn software (version 2.0, PREMIER Biosoft). B, MOLM-13-p53-Vec or MOLM-13-p53-KD cells were treated with MOLM-13 and milademetan (60 nmol/L) or quizartinib (3 nmol/L) or the combination for 24 hours. Correlated signaling pathway proteins were measured with immunoblotting. C, Primary AML samples (three cases; harboring FLT3 mutant/ TP53 WT) and two normal BM samples from normal donors were treated with indicated concentrations of quizartinib and/or milademetan for 2 weeks in <t>methylcellulose</t> medium. CFU-GM colonies were counted, and the percentage of colony forming against the control group was calculated. The data were obtained from triplicated wells, and error bars are presented as mean ± SD. Asterisks indicate the level of statistical significance. *, P < 0.05; **, P < 0.01; ***, P < 0.001 as determined using a two-tailed unpaired t test. BAX, Bcl-2–associated X; CFU-GM, colony-forming unit granulocyte–macrophage; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; NS, no statistical significance.
    Methylcellulose Medium, supplied by STEMCELL Technologies Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/methylcellulose medium/product/STEMCELL Technologies Inc
    Average 90 stars, based on 1 article reviews
    methylcellulose medium - by Bioz Stars, 2026-04
    90/100 stars
    		  Buy from Supplier
    methocult gfm3434 methylcellulose medium  (STEMCELL Technologies Inc)
    90
    STEMCELL Technologies Inc methocult gfm3434 methylcellulose medium
    Combination of Q/M-induced proapoptotic activity is p53-dependent, and the combination treatment impairs clonogenicity in FLT3 mutant/ TP53 WT leukemia blasts. A, MOLM-13-p53-Vec or MOLM-13-p53-KD cells were treated with increasing concentrations of single-agent milademetan or quizartinib or Q/M combination for 48 hours. Apoptosis was measured by FCM with annexin V staining. CIs were calculated using CalcuSyn software (version 2.0, PREMIER Biosoft). B, MOLM-13-p53-Vec or MOLM-13-p53-KD cells were treated with MOLM-13 and milademetan (60 nmol/L) or quizartinib (3 nmol/L) or the combination for 24 hours. Correlated signaling pathway proteins were measured with immunoblotting. C, Primary AML samples (three cases; harboring FLT3 mutant/ TP53 WT) and two normal BM samples from normal donors were treated with indicated concentrations of quizartinib and/or milademetan for 2 weeks in <t>methylcellulose</t> medium. CFU-GM colonies were counted, and the percentage of colony forming against the control group was calculated. The data were obtained from triplicated wells, and error bars are presented as mean ± SD. Asterisks indicate the level of statistical significance. *, P < 0.05; **, P < 0.01; ***, P < 0.001 as determined using a two-tailed unpaired t test. BAX, Bcl-2–associated X; CFU-GM, colony-forming unit granulocyte–macrophage; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; NS, no statistical significance.
    Methocult Gfm3434 Methylcellulose Medium, supplied by STEMCELL Technologies Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/methocult gfm3434 methylcellulose medium/product/STEMCELL Technologies Inc
    Average 90 stars, based on 1 article reviews
    methocult gfm3434 methylcellulose medium - by Bioz Stars, 2026-04
    90/100 stars
    		  Buy from Supplier
    methylcellulose medium methocult h4434  (STEMCELL Technologies Inc)
    90
    STEMCELL Technologies Inc methylcellulose medium methocult h4434
    Combination of Q/M-induced proapoptotic activity is p53-dependent, and the combination treatment impairs clonogenicity in FLT3 mutant/ TP53 WT leukemia blasts. A, MOLM-13-p53-Vec or MOLM-13-p53-KD cells were treated with increasing concentrations of single-agent milademetan or quizartinib or Q/M combination for 48 hours. Apoptosis was measured by FCM with annexin V staining. CIs were calculated using CalcuSyn software (version 2.0, PREMIER Biosoft). B, MOLM-13-p53-Vec or MOLM-13-p53-KD cells were treated with MOLM-13 and milademetan (60 nmol/L) or quizartinib (3 nmol/L) or the combination for 24 hours. Correlated signaling pathway proteins were measured with immunoblotting. C, Primary AML samples (three cases; harboring FLT3 mutant/ TP53 WT) and two normal BM samples from normal donors were treated with indicated concentrations of quizartinib and/or milademetan for 2 weeks in <t>methylcellulose</t> medium. CFU-GM colonies were counted, and the percentage of colony forming against the control group was calculated. The data were obtained from triplicated wells, and error bars are presented as mean ± SD. Asterisks indicate the level of statistical significance. *, P < 0.05; **, P < 0.01; ***, P < 0.001 as determined using a two-tailed unpaired t test. BAX, Bcl-2–associated X; CFU-GM, colony-forming unit granulocyte–macrophage; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; NS, no statistical significance.
    Methylcellulose Medium Methocult H4434, supplied by STEMCELL Technologies Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/methylcellulose medium methocult h4434/product/STEMCELL Technologies Inc
    Average 90 stars, based on 1 article reviews
    methylcellulose medium methocult h4434 - by Bioz Stars, 2026-04
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Combination of Q/M-induced proapoptotic activity is p53-dependent, and the combination treatment impairs clonogenicity in FLT3 mutant/ TP53 WT leukemia blasts. A, MOLM-13-p53-Vec or MOLM-13-p53-KD cells were treated with increasing concentrations of single-agent milademetan or quizartinib or Q/M combination for 48 hours. Apoptosis was measured by FCM with annexin V staining. CIs were calculated using CalcuSyn software (version 2.0, PREMIER Biosoft). B, MOLM-13-p53-Vec or MOLM-13-p53-KD cells were treated with MOLM-13 and milademetan (60 nmol/L) or quizartinib (3 nmol/L) or the combination for 24 hours. Correlated signaling pathway proteins were measured with immunoblotting. C, Primary AML samples (three cases; harboring FLT3 mutant/ TP53 WT) and two normal BM samples from normal donors were treated with indicated concentrations of quizartinib and/or milademetan for 2 weeks in methylcellulose medium. CFU-GM colonies were counted, and the percentage of colony forming against the control group was calculated. The data were obtained from triplicated wells, and error bars are presented as mean ± SD. Asterisks indicate the level of statistical significance. *, P < 0.05; **, P < 0.01; ***, P < 0.001 as determined using a two-tailed unpaired t test. BAX, Bcl-2–associated X; CFU-GM, colony-forming unit granulocyte–macrophage; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; NS, no statistical significance.

    Journal: Clinical Cancer Research

    Article Title: Synergistic Activity of Combined FLT3-ITD and MDM2 Inhibition with Quizartinib and Milademetan in FLT3 -ITD Mutant/ TP53 Wild-type Acute Myeloid Leukemias

    doi: 10.1158/1078-0432.CCR-24-2764

    Figure Lengend Snippet: Combination of Q/M-induced proapoptotic activity is p53-dependent, and the combination treatment impairs clonogenicity in FLT3 mutant/ TP53 WT leukemia blasts. A, MOLM-13-p53-Vec or MOLM-13-p53-KD cells were treated with increasing concentrations of single-agent milademetan or quizartinib or Q/M combination for 48 hours. Apoptosis was measured by FCM with annexin V staining. CIs were calculated using CalcuSyn software (version 2.0, PREMIER Biosoft). B, MOLM-13-p53-Vec or MOLM-13-p53-KD cells were treated with MOLM-13 and milademetan (60 nmol/L) or quizartinib (3 nmol/L) or the combination for 24 hours. Correlated signaling pathway proteins were measured with immunoblotting. C, Primary AML samples (three cases; harboring FLT3 mutant/ TP53 WT) and two normal BM samples from normal donors were treated with indicated concentrations of quizartinib and/or milademetan for 2 weeks in methylcellulose medium. CFU-GM colonies were counted, and the percentage of colony forming against the control group was calculated. The data were obtained from triplicated wells, and error bars are presented as mean ± SD. Asterisks indicate the level of statistical significance. *, P < 0.05; **, P < 0.01; ***, P < 0.001 as determined using a two-tailed unpaired t test. BAX, Bcl-2–associated X; CFU-GM, colony-forming unit granulocyte–macrophage; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; NS, no statistical significance.

    Article Snippet: The cells (0.2 × 10 6 ) were plated in methylcellulose medium (1 mL/well; cat.: 04435; STEMCELL Technologies Inc.) for 2 weeks, exposing them to the indicated drugs (in triplicate per condition).

    Techniques: Activity Assay, Mutagenesis, Staining, Software, Western Blot, Control, Two Tailed Test